Cornerstone Therapeutics, Inc. (CRTX) Tops Q2 EPS by 5c, Revenues Beat Expectations

August 4, 2011 10:37 AM EDT
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q2 adjusted EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $28.04 million versus the consensus estimate of $25.71 million.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings